Table 2.

Tumor Vaccine Products: Advantages and Disadvantages

Product	Advantages	Disadvantages
Single peptide	Easy to produce and standardize Immune monitoring of a single antigen	Prior identification of the single TAA Antigen-loss tumor variants
DCs pulsed with peptide, mRNA or apoptotic bodies	Antigen presentation using both MHC class I and II molecules	Complex production Antigen-loss variants Peptide use requires prior identification of the single TAA
Autologous whole cell tumor vaccine	No need to identify TAAs All tumor antigens likely represented and correct MHC restriction insured	Requires patient tumor sample Complex production
Allogeneic whole cell tumor vaccine	No need to identify TAAs Easier to produce and standardize vs. autologous product MHC mismatch may be overcome by cross priming	Inappropriate tumor antigen presentation Correct antigens may be missing

Modified from Rousseau et al. 2005 [16].

Abbreviations: Dendritic cell (DC); Major histocompatibility complex (MHC); Tumor associated antigen (TAA).